- Home
- SNGX vs RNAZ Comparison
SNGX vs RNAZ Comparison
Compare SNGX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- RNAZ
- Stock Information
- Founded
- SNGX 1987
- RNAZ 2016
- Country
- SNGX United States
- RNAZ United States
- Employees
- SNGX N/A
- RNAZ N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- RNAZ Health Care
- Exchange
- SNGX Nasdaq
- RNAZ Nasdaq
- Market Cap
- SNGX 9.6M
- RNAZ 8.3M
- IPO Year
- SNGX 1987
- RNAZ 2021
- Fundamental
- Price
- SNGX $3.51
- RNAZ $0.34
- Analyst Decision
- SNGX
- RNAZ Strong Buy
- Analyst Count
- SNGX 0
- RNAZ 1
- Target Price
- SNGX N/A
- RNAZ $3.00
- AVG Volume (30 Days)
- SNGX 56.4K
- RNAZ 602.3K
- Earning Date
- SNGX 11-08-2024
- RNAZ 11-26-2024
- Dividend Yield
- SNGX N/A
- RNAZ N/A
- EPS Growth
- SNGX N/A
- RNAZ N/A
- EPS
- SNGX N/A
- RNAZ N/A
- Revenue
- SNGX $364,183.00
- RNAZ N/A
- Revenue This Year
- SNGX N/A
- RNAZ N/A
- Revenue Next Year
- SNGX $76.64
- RNAZ $100.00
- P/E Ratio
- SNGX N/A
- RNAZ N/A
- Revenue Growth
- SNGX N/A
- RNAZ N/A
- 52 Week Low
- SNGX $1.83
- RNAZ $0.22
- 52 Week High
- SNGX $32.00
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- SNGX 49.14
- RNAZ 32.40
- Support Level
- SNGX $3.50
- RNAZ $0.31
- Resistance Level
- SNGX $3.74
- RNAZ $0.49
- Average True Range (ATR)
- SNGX 0.20
- RNAZ 0.05
- MACD
- SNGX 0.01
- RNAZ -0.02
- Stochastic Oscillator
- SNGX 47.37
- RNAZ 9.64
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.